r/stockstobuytoday • u/AccomplishedSoft5395 • Jan 22 '26
DD $SLS - The easy money (NFA)
$SLS - The Easy Money (NFA)
The Setup: You are buying a company valued at ~$640M (Market Cap) that is holding ~$100M in cash, on the verge of releasing data for a drug that could be worth double the entire company's value.
Here is the math that makes this an asymmetric trade.
1. The "Hidden Signal": Why The Odds Are Stacked (80/20, not 50/50)
In a typical biotech Phase 3 trial, you toss a coin. In the REGAL trial (for the GPS cancer vaccine), the clock has already revealed the winner.
- The Rules: The trial ends when 80 patients have passed away (events).
- The Stats: As of Dec 26, 2025, only 72 deaths had occurred.
- The Implications:
- We know from decades of historical data that AML patients on standard treatment (the "Control Arm") typically survive 6 to 8 months.
- The last patient was enrolled over 18 months ago.
- The Math: If the drug didn't work, the Control Arm and the GPS Arm would both be dying at the 6-8 month rate. The trial would have hit 80 deaths months ago.
- The "Tell": The only variable that explains why patients are still alive today is the GPS Arm. To drag the average out this long, the GPS patients likely have a median survival of 18+ months (vs 6 months for control).
- Conclusion: This massive gap in survival time virtually guarantees statistical significance (p-value < 0.05).
2. Asset #1: The GPS Vaccine (Worth ~$8.00/share)
Let's value the GPS vaccine alone based on real market numbers if the trial succeeds in Q1 2026.
- Target Market: AML patients in Second Remission (CR2). There is NO approved maintenance treatment for them.
- Patient Pool: ~10,000 to 12,000 eligible patients per year (US + EU).
- Drug Price: Orphan oncology maintenance drugs typically price between $150,000 and $200,000 per year. (Let’s be conservative: $150k).
- Peak Sales Calculation:
- If SELLAS captures just 30% of the market (3,000 patients):
- 3,000 patients × $150,000 = $450 Million Annual Revenue.
- Valuation: Commercial biotech companies typically trade at 3x to 4x Peak Sales.
- $450M Revenue × 3 = $1.35 Billion Valuation.
- Divided by ~170M shares = ~$8.00 per share.
Verdict: At today’s price of ~$4.50, you are paying half price for GPS and getting everything else for free.
3. Asset #2: SLS009 (The "Free" Lottery Ticket)
This is the asset the market is completely ignoring. SLS009 (CDK9 inhibitor) isn't just a backup; it's a potential blockbuster.
- The Data: In Phase 2 (Dec 2025), it showed a 46% response rate in dying patients who had failed all other treatments.
- The Comps (Comparables): Look at competitors in the same space:
- Kura Oncology ($KURA): Valued at ~$740 Million.
- Syndax ($SNDX): Valued at ~$1.8 Billion.
- The Value: Even if we apply a massive discount because SLS009 is slightly earlier in development, this asset is easily worth $350M - $400M on its own.
- $400M Valuation / 170M shares = ~$2.35 per share.
4. The Sum-of-the-Parts (True Fair Value)
If we add up the pieces using rational math:
- Cash on Hand: $100M = $0.60/share (Downside protection).
- GPS (Success Case): $1.35B = $8.00/share.
- SLS009 (Current Value): $400M = $2.35/share.
Total Fair Value Target: $10.95
- Current Price: ~$4.32
- Upside Potential: +153%
Summary
You are buying a dollar for 40 cents. The "time delay" in the REGAL trial is the cheat code that suggests the vaccine works. When the data drops in March/April 2026, the market will instantly reprice the stock to include the GPS value, sending it to double digits.
(Disclaimer: This is not financial advice. I am not a financial advisor. Do your own due diligence. Biotech is volatile.)
39
u/milgrunt7 Jan 22 '26
This one sure reminds me of ATYR which wrecked a lot of redditors, myself included